newsfilter
← Latest News
GlobeNewswire·

Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

SOUTH SAN FRANCISCO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selecti